EVOKE PHARMA INC's ticker is and the CUSIP is 30049G203. A total of 17 filers reported holding EVOKE PHARMA INC in Q2 2024. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $15,791 | -13.3% | 29,851 | 0.0% | 0.00% | – |
| Q1 2024 | $18,209 | -41.9% | 29,851 | 0.0% | 0.00% | – |
| Q4 2023 | $31,353 | -23.9% | 29,851 | 0.0% | 0.00% | – |
| Q3 2023 | $41,194 | -16.4% | 29,851 | 0.0% | 0.00% | – |
| Q2 2023 | $49,254 | -13.2% | 29,851 | 0.0% | 0.00% | – |
| Q1 2023 | $56,717 | -29.1% | 29,851 | 0.0% | 0.00% | – |
| Q4 2022 | $80,001 | +42.9% | 29,851 | 0.0% | 0.00% | – |
| Q3 2022 | $56,000 | -45.1% | 29,851 | -4.7% | 0.00% | – |
| Q2 2022 | $102,000 | – | 31,336 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VANGUARD GROUP INC | 29,851 | $56,717 | 0.00% |
| Federation des caisses Desjardins du Quebec | 5 | $10 | 0.00% |
| WELLS FARGO & COMPANY/MN | 16 | $30 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| UBS Group AG | 1,107 | $2,103 | 0.00% |
| NewEdge Advisors, LLC | 208 | $395 | 0.00% |
| Lindbrook Capital, LLC | 83 | $158 | 0.00% |
| Concord Wealth Partners | 114 | $217 | 0.00% |
| GEODE CAPITAL MANAGEMENT, LLC | 20,894 | $39,698 | 0.00% |
| BlackRock Inc. | 1,473 | $2,799 | 0.00% |